![Daniel Long](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortuna: 3 M $ al 31/05/2026
Daniel Long currently works at Septerna, Inc., as Senior Vice President-Drug Discovery from 2021.
Dr. Long also formerly worked at Theravance Biopharma, Inc., as Vice President & Head-Medical Chemistry & Biology from 2001 to 2021.
Dr. Long received his undergraduate degree, graduate degree, and doctorate degree from the University of Oxford.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
SEPTERNA, INC. 0,21 % | 22/06/2026 | 96.412 ( 0,21 % ) | 3 M $ | 31/05/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| SEPTERNA, INC. | Corporate Officer/Principal | 01/12/2021 |
| Empresas | Cargo | Fin |
|---|---|---|
| THERAVANCE BIOPHARMA, INC. | Corporate Officer/Principal | 01/12/2021 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 3 |
|---|---|
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Theravance Biopharma, Inc.
 Theravance Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Engages in the discovery, development and commercialization of human therapeutics products for respiratory diseases | Health Technology |
Septerna, Inc.
 Septerna, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that discovers and develops G protein-coupled receptor oral small molecule products for the treatment of hypoparathyroidism | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.
